Syndax Pharmaceuticals Stock Buy Hold or Sell Recommendation
| SNDX Stock | USD 13.08 0.08 0.62% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Syndax Pharmaceuticals is 'Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Syndax Pharmaceuticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Syndax Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Syndax Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide. In addition, we conduct extensive research on individual companies such as Syndax and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Syndax |
Execute Syndax Pharmaceuticals Buy or Sell Advice
The Syndax recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Syndax Pharmaceuticals. Macroaxis does not own or have any residual interests in Syndax Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Syndax Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Syndax Pharmaceuticals Trading Alerts and Improvement Suggestions
| Syndax Pharmaceuticals generated a negative expected return over the last 90 days | |
| Syndax Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (209.36 M) with loss before overhead, payroll, taxes, and interest of (48.19 M). | |
| Syndax Pharmaceuticals currently holds about 350.71 M in cash with (160.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.82. | |
| Syndax Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from investors.com: Heres How Donald Trump Could Shake Up Health Care And Biotech Stocks |
Syndax Pharmaceuticals Returns Distribution Density
The distribution of Syndax Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Syndax Pharmaceuticals' future price movements. The chart of the probability distribution of Syndax Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Syndax Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Syndax Pharmaceuticals returns is essential to provide solid investment advice for Syndax Pharmaceuticals.
| Mean Return | -0.53 | Value At Risk | -5.34 | Potential Upside | 3.98 | Standard Deviation | 4.25 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Syndax Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Syndax Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Syndax Pharmaceuticals, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Syndax Pharmaceuticals back and forth among themselves.
| Shares | Woodline Partners Lp | 2024-09-30 | 1.9 M | Franklin Resources Inc | 2024-09-30 | 1.8 M | Stempoint Capital Lp | 2024-09-30 | 1.7 M | Goldman Sachs Group Inc | 2024-09-30 | 1.6 M | First Turn Management Llc | 2024-09-30 | 1.2 M | Millennium Management Llc | 2024-09-30 | 1.1 M | Soleus Capital Management, L.p. | 2024-09-30 | 1.1 M | Sphera Funds Management Ltd. | 2024-09-30 | 1 M | Aisling Capital Management Lp | 2024-09-30 | 1 M | Blackrock Inc | 2024-09-30 | 8.2 M | Kynam Capital Management, Lp | 2024-09-30 | 5.8 M |
Syndax Pharmaceuticals Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 90.6M | 106.7M | (147.6M) | 221.1M | 254.3M | 267.0M | |
| Free Cash Flow | (71.3M) | 29.0M | (133.9M) | (160.6M) | (144.5M) | (137.3M) | |
| Other Non Cash Items | 816K | 187K | (2.0M) | (14.1M) | (12.7M) | (12.0M) | |
| Net Income | (73.2M) | 24.9M | (149.3M) | (209.4M) | (188.4M) | (179.0M) | |
| End Period Cash Flow | 115.4M | 222.1M | 74.5M | 295.6M | 340.0M | 357.0M | |
| Investments | (142.5M) | (40.7M) | (186.2M) | (3.7M) | (3.4M) | (3.5M) | |
| Change To Netincome | 6.0M | 9.4M | 12.9M | 14.0M | 16.1M | 8.2M |
Syndax Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Syndax Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Syndax Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Syndax stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.55 | |
β | Beta against Dow Jones | 0.71 | |
σ | Overall volatility | 4.38 | |
Ir | Information ratio | -0.13 |
Syndax Pharmaceuticals Volatility Alert
Syndax Pharmaceuticals exhibits very low volatility with skewness of -3.12 and kurtosis of 18.26. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Syndax Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Syndax Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Syndax Pharmaceuticals Fundamentals Vs Peers
Comparing Syndax Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Syndax Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Syndax Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Syndax Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Syndax Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Syndax Pharmaceuticals to competition |
| Fundamentals | Syndax Pharmaceuticals | Peer Average |
| Return On Equity | -0.82 | -0.31 |
| Return On Asset | -0.49 | -0.14 |
| Operating Margin | (7.17) % | (5.51) % |
| Current Valuation | 710.94 M | 16.62 B |
| Shares Outstanding | 85.36 M | 571.82 M |
| Shares Owned By Insiders | 0.81 % | 10.09 % |
| Shares Owned By Institutions | 99.19 % | 39.21 % |
| Number Of Shares Shorted | 21.31 M | 4.71 M |
| Price To Earning | 126.11 X | 28.72 X |
| Price To Book | 3.05 X | 9.51 X |
| Price To Sales | 69.78 X | 11.42 X |
| Gross Profit | (48.19 M) | 27.38 B |
| EBITDA | (229.94 M) | 3.9 B |
| Net Income | (209.36 M) | 570.98 M |
| Cash And Equivalents | 350.71 M | 2.7 B |
| Cash Per Share | 5.82 X | 5.01 X |
| Total Debt | 1.64 M | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 17.19 X | 2.16 X |
| Book Value Per Share | 4.28 X | 1.93 K |
| Cash Flow From Operations | (160.6 M) | 971.22 M |
| Short Ratio | 7.93 X | 4.00 X |
| Earnings Per Share | (3.66) X | 3.12 X |
| Target Price | 36.46 | |
| Number Of Employees | 184 | 18.84 K |
| Beta | 0.92 | -0.15 |
| Market Capitalization | 1.12 B | 19.03 B |
| Total Asset | 612.88 M | 29.47 B |
| Retained Earnings | (902.4 M) | 9.33 B |
| Working Capital | 522.78 M | 1.48 B |
| Current Asset | 79.72 M | 9.34 B |
| Current Liabilities | 13.32 M | 7.9 B |
| Net Asset | 612.88 M |
Note: Acquisition by Gallagher Neil of 69375 shares of Syndax Pharmaceuticals at 22.28 subject to Rule 16b-3 [view details]
Syndax Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Syndax . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Syndax Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Syndax Pharmaceuticals? Buying financial instruments such as Syndax Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Syndax Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Growth Funds Thematic Idea Now
Small Growth Funds
Funds or Etfs that invest in stocks of small to mid-sized companies with above-average risk and growth rate that usually reinvest their earnings back into business. The Small Growth Funds theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Growth Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.